Pfizer (NYSE:PFE) Given New $28.00 Price Target at Cantor Fitzgerald

Pfizer (NYSE:PFE) had its target price upped by investment analysts at Cantor Fitzgerald from $27.00 to $28.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 0.13% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. BMO Capital Markets dropped their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. HSBC upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Scotiabank lifted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.61.

Pfizer Trading Up 1.7%

Shares of NYSE PFE opened at $27.96 on Thursday. The stock has a market capitalization of $159.39 billion, a P/E ratio of 36.80, a price-to-earnings-growth ratio of 1.85 and a beta of 0.32. The business has a fifty day moving average price of $27.56 and a 200 day moving average price of $26.48. Pfizer has a 1-year low of $23.62 and a 1-year high of $29.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business posted $0.78 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer will post 2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. BlackRock Inc. grew its holdings in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp boosted its position in Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock worth $1,512,948,000 after purchasing an additional 5,364,929 shares during the period. Bank of America Corp DE purchased a new position in shares of Pfizer during the 2nd quarter valued at approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Pfizer by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after purchasing an additional 293,029 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. The expanded indication gives Pfizer earlier access to patients in the metastatic-treatment pathway and could broaden TUKYSA’s commercial opportunity. Pfizer’s TUKYSA Gets FDA Nod for Front-Line HER2+ Breast Cancer Maintenance
• Positive Sentiment: Pfizer reported positive Phase 3 results for oral LITFULO in nonsegmental vitiligo, showing meaningful facial and total-body repigmentation with a favorable tolerability profile. Planned regulatory submissions could expand the drug’s use and strengthen Pfizer’s immunology portfolio. Pfizer Posted Positive Phase 3 Vitiligo Results for LITFULO
• Positive Sentiment: The board declared a quarterly dividend of $0.43 per share, or $1.72 annualized, payable December 7 to shareholders of record November 6. The sizable yield may help support demand for PFE among income-oriented investors. Pfizer Declares $0.43 Fourth-Quarter Dividend
• Neutral Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, plant. The move may reduce costs as part of broader restructuring, but it also highlights pressure to streamline operations. Pfizer to Cut Around 330 Jobs in Italy
• Negative Sentiment: Investor commentary remains cautious because Pfizer faces a challenging growth period, recently reported a quarterly loss, and has paid dividends well above reported earnings in some periods. Analysts are also watching competition to the Prevnar vaccine franchise, which generated substantial revenue for Pfizer. Pfizer Stock: Buy, Sell, or Hold?

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.